Quebec City, Canada – Saguaro Biosciences, a pioneering developer of live cell reagents for AI-enhanced discoveries, has announced the successful completion of a $3 million Seed funding round. The round was led by AQC Capital and Anges Québec, with notable participation from Martin Leblanc, Co-Founder and Vice-Chairman of CellCarta Biosciences, along with investments from Investissement Quebec and Ville de Québec.
This funding infusion is earmarked to fuel the commercial expansion of ChromaLive™, Saguaro Biosciences’ cutting-edge reagent platform. ChromaLive™ empowers researchers with time-sensitive imaging and AI-enabled analysis capabilities, revolutionizing the study of cell biology.
Under the leadership of CEO Louis Turcotte, Saguaro Biosciences is committed to advancing life sciences through innovative reagents tailored for AI-driven cell analysis. The flagship product, ChromaLive™, has garnered attention from major pharmaceutical companies, positioning Saguaro Biosciences as a key player in the field of cell biology research.
The platform’s ability to demystify cell biology and expedite the discovery of new therapies underscores its potential to revolutionize the life sciences industry.
Louis Turcotte expressed gratitude for the investors’ support and outlined plans to leverage the seed funding to drive commercial expansion and further enhance ChromaLive™’s capabilities. By empowering researchers with advanced tools for AI-driven cell analysis, Saguaro Biosciences is poised to unlock new frontiers in biomedical research and drug development.